Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Major

Showing results (201-210 of 217) with videos related to

Pageof 22
Sort By:
Frontiers in Neurology|April 8, 2020
Germline Genetic Risk Variants for Progressive Multifocal LeukoencephalopathyPeggy S Eis, Christopher D Bruno, Todd A Richmond, et al.
Acta Neuropathologica Communications|July 15, 2016
BK virus encephalopathy and sclerosing vasculopathy in a patient with hypohidrotic ectodermal dysplasia and immunodeficiencyArmine Darbinyan, Eugene O Major, Susan Morgello, et al.
Journal of Neurovirology|July 17, 2016
JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7David N Soleimani-Meigooni, Katherine E Schwetye, Maria Reyes Angeles, et al.
The New England Journal of Medicine|March 3, 2006
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathyTarek A Yousry, Eugene O Major, Caroline Ryschkewitsch, et al.
The New England Journal of Medicine|October 30, 2001
BK-related polyomavirus vasculopathy in a renal-transplant recipientT Petrogiannis-Haliotis, G Sakoulas, J Kirby, et al.
The New England Journal of Medicine|April 11, 2019
Pembrolizumab Treatment for Progressive Multifocal LeukoencephalopathyIrene Cortese, Pawel Muranski, Yoshimi Enose-Akahata, et al.
The Lancet. Neurology|April 17, 2007
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoringLudwig Kappos, David Bates, Hans-Peter Hartung, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 7, 2021
Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1: From the National Multiple Sclerosis Society Case Conference ProceedingsNidhiben Anadani, Megan Hyland, Roberto Alejandro Cruz, et al.
Journal of Neurovirology|October 15, 2015
Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIVSharon L Nichols, James Bethel, Bill G Kapogiannis, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 12, 2021
Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 2: From the National Multiple Sclerosis Society Case Conference ProceedingsRoberto Alejandro Cruz, Nick Hogan, Jayne Sconzert, et al.
Pageof 22

Showing results (201-210 of 217) with videos related to

Sort By:
Pageof 22
Frontiers in Neurology|April 8, 2020
Germline Genetic Risk Variants for Progressive Multifocal LeukoencephalopathyPeggy S Eis, Christopher D Bruno, Todd A Richmond, et al.
Acta Neuropathologica Communications|July 15, 2016
BK virus encephalopathy and sclerosing vasculopathy in a patient with hypohidrotic ectodermal dysplasia and immunodeficiencyArmine Darbinyan, Eugene O Major, Susan Morgello, et al.
Journal of Neurovirology|July 17, 2016
JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7David N Soleimani-Meigooni, Katherine E Schwetye, Maria Reyes Angeles, et al.
The New England Journal of Medicine|March 3, 2006
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathyTarek A Yousry, Eugene O Major, Caroline Ryschkewitsch, et al.
The New England Journal of Medicine|October 30, 2001
BK-related polyomavirus vasculopathy in a renal-transplant recipientT Petrogiannis-Haliotis, G Sakoulas, J Kirby, et al.
The New England Journal of Medicine|April 11, 2019
Pembrolizumab Treatment for Progressive Multifocal LeukoencephalopathyIrene Cortese, Pawel Muranski, Yoshimi Enose-Akahata, et al.
The Lancet. Neurology|April 17, 2007
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoringLudwig Kappos, David Bates, Hans-Peter Hartung, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 7, 2021
Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1: From the National Multiple Sclerosis Society Case Conference ProceedingsNidhiben Anadani, Megan Hyland, Roberto Alejandro Cruz, et al.
Journal of Neurovirology|October 15, 2015
Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIVSharon L Nichols, James Bethel, Bill G Kapogiannis, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 12, 2021
Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 2: From the National Multiple Sclerosis Society Case Conference ProceedingsRoberto Alejandro Cruz, Nick Hogan, Jayne Sconzert, et al.
Pageof 22